Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/143530
Full metadata record
DC FieldValueLanguage
dc.creatorPestana, A
dc.creatorBatista, R
dc.creatorCelestino, R
dc.creatorCanberk, S
dc.creatorSobrinho-Simões, M
dc.creatorSoares, P
dc.date.accessioned2022-08-29T14:35:31Z-
dc.date.available2022-08-29T14:35:31Z-
dc.date.issued2020
dc.identifier.issn2072-6694
dc.identifier.urihttps://hdl.handle.net/10216/143530-
dc.description.abstractThe presence of TERT promoter (TERTp) mutations in thyroid cancer have been associated with worse prognosis features, whereas the extent and meaning of the expression and activation of TERT in thyroid tumours is still largely unknown. We analysed frozen samples from a series of benign and malignant thyroid tumours, displaying non-aggressive features and low mutational burden in order to evaluate the presence of TERTp mutations and TERT mRNA expression in these settings. In this series, TERTp mutations were found in 2%, only in malignant cases, in larger cancers, and from older patients. TERT mRNA expression was detected in both benign and malignant tumours, with increased frequencies in the malignant tumours with aggressive histotypes, larger tumours, and from older patients. In benign tumours, TERT mRNA expression was found in 17% of the follicular thyroid adenoma (FTA) with increased levels of expression in smaller tumours and associated with the presence of thyroiditis. TERTp mutations and TERT mRNA expression are correlated with worse prognosis features in malignant thyroid tumours, whereas TERT mRNA expression in the benign tumours is associated with the presence of thyroiditis.
dc.description.sponsorshipThis study was supported by FCT, the Portuguese Foundation for Science and Technology through a PhD grant to AP SFRH/BD/110617/2015 and RB SFRH/BD/111321/2015. This work was financed by FEDER—Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020—Operacional Programme for Competitiveness and Internationalization (POCI), Portugal 2020, and by Portuguese funds through FCT-Fundação para a Ciência e a Tecnologia/Ministério da Ciência, Tecnologia e Inovação in the framework of the project “Institute for Research and Innovation in Health Sciences” (POCI-01-0145-FEDER-007274). Additional funding by the European Regional Development Fund (ERDF) through the Operational Programme for Competitiveness and Internationalization—COMPETE2020, and Portuguese national funds via FCT, under project POCI-01-0145-FEDER-016390: CANCEL STEM and from the FCT, under the project POCI-01-0145-FEDER-031438: The other faces of telomerase: Looking beyond tumour immortalization (PDTC/MED_ONC/31438/2017).
dc.language.isoeng
dc.publisherMDPI
dc.relationinfo:eu-repo/grantAgreement/FCT/POR_NORTE/SFRH%2FBD%2F110617%2F2015/PT
dc.relationinfo:eu-repo/grantAgreement/FCT/POR_NORTE/SFRH%2FBD%2F111321%2F2015/PT
dc.relation.ispartofCancers, vol.12(7):1846
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectImmortalization
dc.subjectTelomerase
dc.subjectTERT expression
dc.subjectTERT promoter mutations
dc.subjectThyroid tumours
dc.titleComprehensive assessment of tert mRNA expression across a large cohort of benign and malignant thyroid tumours
dc.typeArtigo em Revista Científica Internacional
dc.contributor.uportoInstituto de Investigação e Inovação em Saúde
dc.identifier.doi10.3390/cancers12071846
dc.relation.publisherversionhttps://www.mdpi.com/2072-6694/12/7/1846
Appears in Collections:I3S - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
10.3390-cancers12071846.pdf2.48 MBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons